Zai Lab licenses TIVDAK from Seagen for China, HK, Macau, Taiwan; $30M upfront plus milestones up to $263M

Zai Lab Ltd

Zai Lab pays $30M upfront, up to $78M in dev/reg milestones, and up to $185M in sales milestones.
Seagen receives tiered royalties from mid-teens to low twenties on net sales in licensed territory.
Payments shared 50/50 with Genmab under existing Seagen/Genmab co-development agreement.
TIVDAK is FDA-approved for recurrent/metastatic cervical cancer; Phase 3 trial (innovaTV 301) ongoing.
Approximately 110,000 new cervical cancer cases annually in China, representing significant unmet need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.